List of Mapi Pharma patents

Patents where

Current Assignee

Name

Mapi Pharma

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent RE49251 Depot systems comprising glatiramer or pharmacologically acceptable salt thereof	Patent RE49251 was granted and assigned to Mapi Pharma on October, 2022 by the United States Patent and Trademark Office.	Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	RE49251	October 18, 2022
‌ US Patent 11471421 Process for preparing microparticles containing glatiramer acetate		Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	11471421	October 18, 2022
‌ US Patent 8975244 Process and intermediates for the preparation of abiraterone acetate	Patent 8975244 was granted and assigned to Mapi Pharma on March, 2015 by the United States Patent and Trademark Office.	Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	8975244	March 10, 2015
‌ US Patent 9617241 Intermediate compounds and process for the preparation of efinaconazole	Patent 9617241 was granted and assigned to Mapi Pharma on April, 2017 by the United States Patent and Trademark Office.	Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	9617241	April 11, 2017
‌ US Patent 8735627 Intermediate compounds and process for the preparation of fingolimod	Patent 8735627 was granted and assigned to Mapi Pharma on May, 2014 by the United States Patent and Trademark Office.		Mapi Pharma	United States Patent and Trademark Office	8735627	May 27, 2014
‌ US Patent 9994522 Amorphous form of apremilast	Patent 9994522 was granted and assigned to Mapi Pharma on June, 2018 by the United States Patent and Trademark Office.	Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	9994522	June 12, 2018
‌ US Patent 11026908 Extended release dosage forms of pregabalin	Patent 11026908 was granted and assigned to Mapi Pharma on June, 2021 by the United States Patent and Trademark Office.	Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	11026908	June 8, 2021
‌ US Patent 9006188 Co-crystals of dapagliflozin	Patent 9006188 was granted and assigned to Mapi Pharma on April, 2015 by the United States Patent and Trademark Office.	Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	9006188	April 14, 2015
‌ US Patent 9453024 Polymorphs of darunavir	Patent 9453024 was granted and assigned to Mapi Pharma on September, 2016 by the United States Patent and Trademark Office.	Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	9453024	September 27, 2016
‌ US Patent 9102592 Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium	Patent 9102592 was granted and assigned to Mapi Pharma on August, 2015 by the United States Patent and Trademark Office.	Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	9102592	August 11, 2015
‌ US Patent 9096574 Polymorphs of perampanel	Patent 9096574 was granted and assigned to Mapi Pharma on August, 2015 by the United States Patent and Trademark Office.	Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	9096574	August 4, 2015
‌ US Patent 8410176 Intermediate compounds and processes for the preparation of tapentadol and related compounds	Patent 8410176 was granted and assigned to Mapi Pharma on April, 2013 by the United States Patent and Trademark Office.		Mapi Pharma	United States Patent and Trademark Office	8410176	April 2, 2013
‌ US Patent 9200114 Random pentapolymer for treatment of autoimmune diseases	Patent 9200114 was granted and assigned to Mapi Pharma on December, 2015 by the United States Patent and Trademark Office.	Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	9200114	December 1, 2015
‌ US Patent 10111867 Process and intermediates for the preparation of perampanel	Patent 10111867 was granted and assigned to Mapi Pharma on October, 2018 by the United States Patent and Trademark Office.	Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	10111867	October 30, 2018
‌ US Patent 8865742 Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium	Patent 8865742 was granted and assigned to Mapi Pharma on October, 2014 by the United States Patent and Trademark Office.		Mapi Pharma	United States Patent and Trademark Office	8865742	October 21, 2014
‌ US Patent 8772503 Processes for the preparation of deferasirox, and deferasirox polymorphs	Patent 8772503 was granted and assigned to Mapi Pharma on July, 2014 by the United States Patent and Trademark Office.		Mapi Pharma	United States Patent and Trademark Office	8772503	July 8, 2014
‌ US Patent 9206197 Amorphous form of dolutegravir	Patent 9206197 was granted and assigned to Mapi Pharma on December, 2015 by the United States Patent and Trademark Office.		Mapi Pharma	United States Patent and Trademark Office	9206197	December 8, 2015
‌ US Patent 8829208 Process for the preparation of darunavir and darunavir intermediates	Patent 8829208 was granted and assigned to Mapi Pharma on September, 2014 by the United States Patent and Trademark Office.		Mapi Pharma	United States Patent and Trademark Office	8829208	September 9, 2014
‌ US Patent 8921415 Polymorphs of darunavir	Patent 8921415 was granted and assigned to Mapi Pharma on December, 2014 by the United States Patent and Trademark Office.		Mapi Pharma	United States Patent and Trademark Office	8921415	December 30, 2014
‌ US Patent 8841447 Process for the preparation of alogliptin	Patent 8841447 was granted and assigned to Mapi Pharma on September, 2014 by the United States Patent and Trademark Office.		Mapi Pharma	United States Patent and Trademark Office	8841447	September 23, 2014
‌ US Patent 8796226 Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof	Patent 8796226 was granted and assigned to Mapi Pharma on August, 2014 by the United States Patent and Trademark Office.		Mapi Pharma	United States Patent and Trademark Office	8796226	August 5, 2014
‌ US Patent 11167003 Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems	Patent 11167003 was granted and assigned to Mapi Pharma on November, 2021 by the United States Patent and Trademark Office.	Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	11167003	November 9, 2021
‌ US Patent 8981095 Intermediate compounds and process for the preparation of lurasidone and salts thereof	Patent 8981095 was granted and assigned to Mapi Pharma on March, 2015 by the United States Patent and Trademark Office.		Mapi Pharma	United States Patent and Trademark Office	8981095	March 17, 2015
‌ US Patent 8377885 Depot systems comprising glatiramer or pharmacologically acceptable salt thereof	Patent 8377885 was granted and assigned to Mapi Pharma on February, 2013 by the United States Patent and Trademark Office.		Mapi Pharma	United States Patent and Trademark Office	8377885	February 19, 2013
‌ US Patent 10493122 Sublingual delivery of glatiramer acetate	Patent 10493122 was granted and assigned to Mapi Pharma on December, 2019 by the United States Patent and Trademark Office.	Mapi Pharma	Mapi Pharma	United States Patent and Trademark Office	10493122	December 3, 2019

Results per page:

27 results

0 selected

27 results

0 selected